Bayer EU approval
This article was originally published in The Tan Sheet
Executive Summary
The European Commission has approved Bayer's acquisition of Roche's consumer unit, the firms announce Nov. 19. Bayer's enhanced segment now includes Supradyn multivitamins, topical ointment Bepanthen, antacid Rennie and vitamin C supplement Redoxon. The transaction is valued at $3.1 bil. and closing is expected by year-end, Bayer said. As a condition of approval, the EC is requiring Roche to sell regional rights to several of its products, including antifungals Caldesene and Desenex in Ireland and Aspro and Aspro C in Austria. Roche announced its intention to sell its consumer unit to Bayer in July, the same day it announced the licensing of U.S. marketing rights to weight-loss drug Xenical to GlaxoSmithKline (1"The Tan Sheet" July 26, 2004, p. 3)...